Debiopharm finalizes a strategic partnership to leverage WhiteLab’s proprietary AI platform for identifying agents that provide targeting properties to non-viral vectors in oncology.
Debiopharm, a privately-owned, Swiss-based, biopharmaceutical company aiming to establish tomorrow’s standard-of-care to cure cancer and infectious diseases, announced the signing of a partnership with WhiteLab Genomics (WLG), a Paris and Boston-based biotech company specializing in Artificial Intelligence for Genomic Medicine R&D. This collaboration aims to achieve two key objectives. The first is to identify cancer-specific receptors that are overexpressed on the surface of cancer cells. The second is to find lead candidates capable of binding to these receptors. Once identified, these agents will be attached to the surface of lipid nanoparticles (LNPs) to enhance active tissue targeting
Lipid nanoparticles (LNPs) have emerged as a gold standard vector for drug delivery with the potential to transform the oncology landscape, particularly the genomic medicine field, through their high delivery efficacy. One of the challenges with LNPs is their tendency to accumulate in non-target organs like the liver, which limits their distribution to the desired site. To maximize LNPs potential, WLG is set to deploy its AI-powered platform to explore innovative in silico approaches for enhancing the targeted delivery capabilities of LNPs, creating new opportunities for therapeutic applications.
Also Read: Massive Bio Launches Patient Connect for Global Cancer Trials
As a key investor in WLG, Debiopharm has consistently supported the company’s innovative approaches and cutting-edge solutions through Debiopharm’s Innovation Fund. This collaboration provides a significant opportunity to validate the potential of WLG’s AI platform and strengthen their ongoing relationship.
“WhiteLab’s innovative AI platform represents a significant advancement in the field of targeted cancer therapy. By improving the specificity and delivery of lipid nanoparticles, we aim to provide more effective treatments for patients suffering from hormonal cancers,” said David Del Bourgo, CEO co-founder of WLG. “Our collaboration with a leading player such as Debiopharm further demonstrates our focus on developing cutting-edge solutions that have the potential to transform cancer treatments.”
“As a company specialized in drug development, we know the hardships of the field and therefore we recognize the added value of AI powered platforms like the WhiteLab Genomics’ platform applied to the early stages of drugs R&D. We look forward to fully exploiting the potential of AI based solutions to develop drugs, de-risk assets, de-risk any toxicity, and ensure that we bring the most efficacious and personalized drugs to patients.” said Betrand Ducrey, CEO of Debiopharm.
Source: Businesswire
